Insider Selling: InfuSystem Holdings, Inc. (NYSE:INFU) CEO Sells 20,000 Shares of Stock

InfuSystem Holdings, Inc. (NYSE:INFU) CEO Richard Dilorio sold 20,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.32, for a total transaction of $186,400.00. Following the completion of the transaction, the chief executive officer now directly owns 436,659 shares of the company’s stock, valued at approximately $4,069,661.88. The trade was a 4.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Richard Dilorio also recently made the following trade(s):

• On Wednesday, November 27th, Richard Dilorio sold 5,398 shares of InfuSystem stock. The stock was sold at an average price of $8.87, for a total value of $47,880.26.

InfuSystem Stock Performance

INFU opened at $8.87 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The company’s 50 day simple moving average is $7.39. InfuSystem Holdings, Inc. has a one year low of $5.74 and a one year high of $10.99. The company has a market capitalization of $188.47 million, a PE ratio of 147.77 and a beta of 1.45.

Hedge Funds Weigh In On InfuSystem

Hedge funds have recently bought and sold shares of the business. Kings Path Partners LLC bought a new stake in shares of InfuSystem during the second quarter worth $514,000. First Eagle Investment Management LLC lifted its holdings in InfuSystem by 10.0% during the 2nd quarter. First Eagle Investment Management LLC now owns 666,048 shares of the company’s stock valued at $4,549,000 after buying an additional 60,813 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in InfuSystem in the 2nd quarter valued at about $272,000. Squarepoint Ops LLC bought a new position in InfuSystem in the 2nd quarter worth about $230,000. Finally, Panagora Asset Management Inc. purchased a new position in shares of InfuSystem during the second quarter worth approximately $208,000. Institutional investors own 71.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on INFU. StockNews.com upgraded InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th. B. Riley assumed coverage on shares of InfuSystem in a report on Thursday, September 26th. They issued a “buy” rating and a $13.00 target price for the company.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.